Evidence map›Paper›PMID 30553734›Full record

ArticleBioorganic & medicinal chemistry letters2019

Erythrofordins D and E, two new cassaine-type diterpenes from Erythrophleum suaveolens.

Tanja Grkovic, Jason R Evans, Rhone K Akee, Liang Guo, Myrtle Davis, Johnson Jato, Paul G Grothaus, Michelle Ahalt-Gottholm, Melinda Hollingshead, Jerry M Collins and 2 more

Abstract read
In one paragraph

Article in Bioorganic & medicinal chemistry letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Nigerian medicinal plants with potential anticancer activity-a review.Exploration of targeted anti-tumor therapy · 2024
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Tanja GrkovicNatural Products Support Group, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research Sponsored by the National Cancer Institute, Frederick, MD 21702, United States. Electronic address: tanja.grkovic@nih.gov.
Jason R EvansData Management Services Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, United States; Natural Products Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick, MD 21702, United States.
Rhone K AkeeNatural Products Support Group, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research Sponsored by the National Cancer Institute, Frederick, MD 21702, United States.
Liang GuoLaboratory of Investigative Toxicology, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research Sponsored by the National Cancer Institute, Frederick, MD 21702, United States.
Myrtle DavisToxicology and Pharmacology Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, United States.
Johnson JatoFaculty of Medicine and Biomedical Sciences, B. P. 92, University of Yaounde, Yaounde, Cameroon.
Paul G GrothausNatural Products Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick, MD 21702, United States.
Michelle Ahalt-GottholmBiological Testing Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick, MD 21702, United States.
Melinda HollingsheadBiological Testing Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick, MD 21702, United States.
Jerry M CollinsDevelopmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick, MD 21702, United States.
David J NewmanNatural Products Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick, MD 21702, United States.
Barry R O'KeefeNatural Products Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick, MD 21702, United States; Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, United States. Electronic address: okeefeba@mail.nih.gov.
National Cancer Institute · USLeidos (United States) · USFrederick National Laboratory for Cancer Research · USTarget (United States) · USUniversité de Yaoundé I · CM

Funding

NCI Program for Natural Products Discovery - CuresZIABC011854 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI OKEEFE, BARRY · 2020 to 2025
$5.2M
CCR NIH HHS HHSN261200800001CIntramural NIH HHS Z99 CA999999NCI NIH HHS HHSN261200800001E
6 · The paper itself

Abstract

Two new cassaine-type diterpenoids, namely erythrofordins D (1) and E (2), sourced from a Cameroon collection of Erythrophleum suaveolens were isolated and assessed for anti-tumor activity. In the NCI-60 cancer cell assay, erythrofordins D (1) and E (2) were found to be cytotoxic in the low micro molar ranges with a mean GI

Indexed as

CaesalpiniaCell SurvivalDiterpenesDose-Response Relationship, DrugHumansMolecular StructureMyocytes, CardiacStructure-Activity RelationshipDiterpenesCardiotoxicityCOMPAREErythrofordinNatural productNCI-60

Identifiers

PMID30553734
PMCPMC6330894
OpenAlexW2905024029

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.